TITLE

Phytotoxicity assessment of diclofenac and its phototransformation products

AUTHOR(S)
Schmitt-Jansen, Mechthild; Bartels, Peter; Adler, Nicole; Altenburger, Rolf
PUB. DATE
February 2007
SOURCE
Analytical & Bioanalytical Chemistry;Feb2007, Vol. 387 Issue 4, p1389
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The occurrence of pharmaceuticals in the environment is an emerging issue. Several studies observed that the non-steroidal anti-inflammatory drug diclofenac is ubiquitously present in most of the surveyed surface waters, worldwide. Phototransformation of diclofenac was reported from laboratory assays as well as in natural water systems, raising the question of possible adverse effects of the phototransformation products of diclofenac to aquatic organisms. In this study the phytotoxicity of diclofenac exposed to natural sunlight was evaluated using synchronized cultures of the unicellular chlorophyte Scenedesmus vacuolatus. Diclofenac dissolved in ultra-pure water at 50 mg L−1 was exposed to natural midsummer sunlight for a maximum of 145 h. Twice a day subsamples were taken for chromatography and parallel phytotoxicity assessment. Inhibition of algal reproduction of the initial diclofenac solution was in the mg L−1 range indicating no specific toxicity of diclofenac towards S. vacuolatus. Fast degradation of diclofenac was observed with half lives between 3.3 and 6.4 h during the first and the third day of exposure, respectively. Phytotoxicity increased after 3.5 h of exposure of diclofenac to sunlight and showed a maximum of sixfold enhanced toxicity after 53 h of exposure to sunlight. Several phototransformation products were found during the experiment. The time courses of the relative concentration of three transformation products significantly correlated with enhanced phytotoxicity during the experiment. This indicates a high toxicity potential of phototransformation products of diclofenac at concentration levels that may come close to environmental concentrations of residual diclofenac after degradation. We conclude that toxicity assessment of phototransformation products should be included in the risk assessment of pharmaceuticals in the environment.
ACCESSION #
23905341

 

Related Articles

  • Gene expression profiling in zebrafish embryos exposed to diclofenac, an environmental toxicant. Felice, Bruna; Copia, Luisa; Guida, Marco // Molecular Biology Reports;Mar2012, Vol. 39 Issue 3, p2119 

    Pharmaceuticals are continually released in the environment and therefore pollution from drugs is a pressing problem in the environment. Diclofenac, 2-[(2,6-dichlorophenyl)amino]phenylacetic acid is a FDA approved non-steroidal anti-inflammatory drug (NSAID) for the treatment of inflammation....

  • FULL CIRCLE: Drugs, the environment and our health. BATT, SHARON // Network Magazine of the Canadian Women's Health Network;Fall/Winter2008/2009, Vol. 11 Issue 1, p14 

    The article focuses on the ill effects of the drugs found in drinking water on women's health. Abby C. Collier, a pharmacologist at the University of Hawaii in Manoa, Hawaii, found five drugs of greatest concern for pregnant women including ethinyl estradiol, norethindrone, diazepam,...

  • Nonsteroidal-Induced Benign Strictures of the Caecum: A Case Report And Review Of The Literature. Gopalswamy, S.; Arumugam, P. J.; Feldman, M. // Internet Journal of Surgery;2008, Vol. 17 Issue 1, p5 

    A rare complication seen with chronic use of sustained-release non-steroidal anti-inflammatory drugs (NSAIDs) is formation of bowel strictures and diaphragm-like disease with characteristic histological appearance of submucosal fibrosis. They are thought to result from alterations in enterocyte...

  • Analgesic Efficacy and Safety of Lornoxicam Quick-Release Formulation Compared with Diclofenac Potassium: Randomised, Double-Blind Trial in Acute Low Back Pain. Yakhno, N.; Guekht, A.; Skoromets, A.; Spirin, N.; Strachunskaya, E.; Ternavsky, A.; Olsen, K. J.; Moller, P. L. // Clinical Drug Investigation;2006, Vol. 26 Issue 5, p267 

    BACKGROUND: NSAIDs are widely used for patients presenting with low back pain. A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of pain relief compared with the standard tablet formulation. METHODS: Time to onset of pain relief...

  • Implementing Ecopharmacovigilance in Practice: Challenges and Potential Opportunities. Holm, Gisela; Snape, Jason; Murray-Smith, Richard; Talbot, John; Taylor, David; Sörme, Pernilla // Drug Safety;2013, Vol. 36 Issue 7, p533 

    Ecopharmacovigilance (EPV) is a developing science and it is currently very unclear what it might mean in practice. We have performed a comparison between pharmacovigilance (PV) and EPV and have identified that there are similarities, but also some important differences that must be considered...

  • Diclofenac hepatitis. Dunk, A.A.; Walt, R.P.; Jenkins, W.J.; Sherlock, S.S. // British Medical Journal (Clinical Research Edition);5/29/1982, Vol. 284 Issue 6329, p1605 

    Examines the use of diclofenac as non-steroidal anti-inflammatory agent. Side effects of the drug; Development of liver disease after diclofenac treatment; Impairment of liver function test after treatment.

  • "THE ANALGESIC STEPLADDER - MISSING RUNGS". Bell, Philip R.; Adair, Robin A. // Ulster Medical Journal;Jan2014, Vol. 83 Issue 1, p47 

    A letter to the editor is presented about the adverse effects of the analgesic diclofenac.

  • Pennsaid.  // Royal Society of Medicine: Medicines;2002, p430 

    This article presents information on pennsaid, a proprietary, prescription-only preparation of the (NSAID) non-narcotic analgesic diclofenac sodium, which also has counter-irritant, or rubefacient, actions. It can be used for the symptomatic relief of underlying joint pain of osteoarthritis and...

  • Rhumalgan CR.  // Royal Society of Medicine: Medicines;2002, p475 

    The article presents information rhumalgan CR, a proprietary, prescription-only version of the non-narcotic analgesic and antirheumatic diclofenac sodium. It can be used to treat arthritic and rheumatic pain and other musculoskeletal disorders. It is available as modified-release tablets.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics